AP -- Alimera Sciences Inc., a biopharmaceutical company that specializes in prescription eye drugs, plans an initial public offering of its stock this week. Alimera is conducting two late-stage clinical trials for Iluvien, which aims to treat diabetic macular edema, a retinal disease that can lead to blindness. The company called Iluvien its most advanced drug candidate.